(Updates the latest stock movement in the first paragraph and the headline.)
Harmony Biosciences (HRMY) shares were down about 4.4% after the company said Chief Financial Officer Glenn Reicin stepped down to pursue other opportunities.
The company reported Thursday preliminary Q2 net product revenue for Wakix of around $261 million, up 30% year over year.
Analysts polled by FactSet expect $249.5 million.
The company reiterated its full-year 2026 net product revenue guidance of $1.0 billion to $1.04 billion.
Analysts expect $1.01 billion.
In addition, the company said Chief Financial Officer Glenn Reicin stepped down to pursue other opportunities, effective immediately.
The company said it named Stephen Mollichella, currently the controller, as interim principal financial officer as it conducts its search for a permanent finance chief.
Harmony will report its Q2 financial results on Aug. 4.
Price: $33.38, Change: $-1.53, Percent Change: -4.37%